Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
09:00am, Monday, 09'th Dec 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term
10:55am, Tuesday, 03'rd Dec 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
03:18pm, Wednesday, 27'th Nov 2024
NUPLAZID and DAYBUE are each delivering double-digit percentage net product sales growth. Company is on track to reach more than $1 billion in annualized net product sales in 2025. Next phase of growt
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
11:11am, Wednesday, 27'th Nov 2024
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
04:05pm, Tuesday, 26'th Nov 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and c
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
04:05pm, Thursday, 21'st Nov 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: Citi's 2024 Global Healthcare Conference Fireside
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 15'th Nov 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on November 8, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
10:56am, Tuesday, 12'th Nov 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Acadia Pharmaceuticals: Proving The Naysayers Wrong
10:50am, Monday, 11'th Nov 2024
Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some 20% last week following Q3 results. The company beat both top and bottom-line expectations and also
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
11:05am, Thursday, 07'th Nov 2024
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
08:09pm, Wednesday, 06'th Nov 2024
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates
06:21pm, Wednesday, 06'th Nov 2024
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to loss of $0.40 per share a year ago.
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
04:05pm, Tuesday, 05'th Nov 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Vou
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Wednesday, 30'th Oct 2024
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
06:41pm, Thursday, 17'th Oct 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. f
